EpiStem Ltd to Provide Preclinical Efficacy Testing Services for Exponential Biotherapies Inc. (EBI)

Published: Apr 01, 2008

MANCHESTER, UK--(Marketwire - April 01, 2008) - Epistem (LSE: EHP) announced today that Exponential Biotherapies, Inc. (EBI) of Virginia, USA, have contracted Epistem to provide their specialised preclinical efficacy testing services for agents likely to protect the gastrointestinal tract against radiation damage. The first compound that Epistem will assess is EBI's lead candidate drug, EA-230, which is a small peptide immunoregulator, which has shown the potential to treat (minimise) radiation insult and could therefore be administered following a terrorist nuclear attack to reduce the level of intestinal related radiation sickness.

Back to news